We also investigated the weight of serum markers for the diagnosis of RA-ILD, in comparison with known RA-ILD risk factors including age at onset, disease duration, smoking status, gender, ACPA, CRP levels, treatment with MTX and targeted biologic therapies. This evidence concerns the gene PRTN3 and rheumatoid arthritis.